Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag for T-DM1-induced thrombocytopenia in breast cancer (single-arm phase 2)
ChiCTR2500112127Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in Thrombocytopenia and breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Proportion of patients with platelet count <100 × 10^9/L during T-DM1 treatment cycles despite Herombopag prophylaxis. Started Nov 2025; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopeniabreast cancer
Beyond the preview
Go deeper on ChiCTR2500112127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112127.